Skip to content

Retrospective study on screening biomarkers for gynecological malignant tumors based on blood metabolomics technology

Retrospective study on screening biomarkers for gynecological malignant tumors based on blood metabolomics technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099940
Enrollment
Unknown
Registered
2025-04-01
Start date
2024-03-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Gold Standard:Organizational pathological diagnosis
Index test:Non-targeted metabolomics detection

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Women aged >= 18 years old; 2.Read and fully understand, sign an informed consent form, and be able to provide blood samples for metabolom; 3.Confirmed by biopsy/postoperative pathology or clinically diagnosed as primary cervical cancer, endometrial cancer, and ovarian cancer through comprehensive evaluation by clinical doctors.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation period; 2.Emergency or requiring rescue; 3.History of blood transfusion within 7 days prior to sampling; 4.People who have received organ transplantation or have previously received non autologous (allogeneic) bone marrow or stem cell transplantation; 5.Having a history of malignant tumors within 5 years or undergoing any anti-tumor treatment before sampling; 6.Simultaneously merging multiple primary malignant tumors.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;

Countries

China

Contacts

Public ContactHao Wen

Fudan University Shanghai Cancer Center

wenhao_fdc@163.com+86 21 64175590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 19, 2026